Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Study suggests that about 70% of total Alzheimer's risk is hereditary

Alzheimer's, and intervene to reduce the risk of the disease? We may be closer to that goal, thanks to a team at the University of Kentucky. Researchers affiliated with the UK Sanders-Brown Center on Aging have completed new work in Alzheimer's genetics; the research is detailed in a paper published today in the Journal of Neuroscience.

16 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

Specific mutations in FLT3 receptor can contribute to acute myeloid leukemia

Specific mutations (N676K) in the FLT3 receptor can contribute to the development of acute myeloid leukemia. The FLT3 receptor regulates cell growth, while activating gene mutations promote the uncontrolled proliferation of white blood cells. These findings were reported in the specialist journal Blood by a group of scientists from the Helmholtz Zentrum München and the Hospital of the Ludwig Maximilians University in Munich as part of a clinical research collaboration with the German Cancer Consortium.

3 Aug 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

ERYTECH reports fast take-off of GRASPA Phase IIb trial in patients with acute myeloid leukemia

ERYTECH, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces a fast take-off of its Phase IIb study in Acute Myeloid Leukemia.

4 Jul 2013

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.

27 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

DCPrime completes DCP-001 Phase I/IIa study in patients with acute myeloid leukemia

Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia.

28 May 2013

Liposomal anthracycline-based chemotherapy effective for children with leukemia: Study

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology.

24 May 2013

Caltech biologists show that microRNA-146a protects stem cells during inflammation

When infections occur in the body, stem cells in the blood often jump into action by multiplying and differentiating into mature immune cells that can fight off illness. But repeated infections and inflammation can deplete these cell populations, potentially leading to the development of serious blood conditions such as cancer.

22 May 2013

New computational method may help track tumor progression, risk of relapse

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual cells. These technologies have led to new challenges, however, as scientists now struggle with how to make sense of the resulting trove of data. Now a solution may be at hand.

20 May 2013

Viewpoints: When a doctor should keep quiet; 2 views of hospital pricing; Stem cell 'snake oil'

In medical school, we were taught not to withhold information from our patients or to be "paternal" in making decisions for them. We internalized the idea that fully informed patients are better equipped to make treatment decisions.

17 May 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

From Beckman Coulter Life Sciences - Flow Cytometry 16 May 2013

Secure cloud-based computing system to access, analyze human genomic cancer information

The University of Chicago launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.

16 May 2013

Researchers identify microRNA-155 as prognostic marker, treatment target in patients with AML

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with acute myeloid leukemia that has normal-looking chromosomes under the microscope (that is, cytogenetically normal acute myeloid leukemia, or CN-AML).

14 May 2013

Powerful data-sifting algorithms help untangle complex genetics of cancer

Powerful data-sifting algorithms developed by computer scientists at Brown University are helping to untangle the profoundly complex genetics of cancer.

2 May 2013

Genomics-based testing could change recommended course of treatment for endometrial cancer

The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women.